These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Dementia and mild cognitive impairment (MCI) are major concerns for seniors, especially those over 65. About 10% of the US ...

This accumulation could elevate their risk of developing late-onset amyloid-related disorders, such as Alzheimer’s disease.

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Researchers have uncovered a link between COVID-19 and blood markers linked to faulty proteins in the brain. The analysis, ...

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...